[go: up one dir, main page]

MX2012004769A - Compuestos de bisfosfonato para tratar transtornos del metabolismo oseo. - Google Patents

Compuestos de bisfosfonato para tratar transtornos del metabolismo oseo.

Info

Publication number
MX2012004769A
MX2012004769A MX2012004769A MX2012004769A MX2012004769A MX 2012004769 A MX2012004769 A MX 2012004769A MX 2012004769 A MX2012004769 A MX 2012004769A MX 2012004769 A MX2012004769 A MX 2012004769A MX 2012004769 A MX2012004769 A MX 2012004769A
Authority
MX
Mexico
Prior art keywords
compounds
treating bone
bone metabolism
metabolism disorders
bisphosphonate compounds
Prior art date
Application number
MX2012004769A
Other languages
English (en)
Inventor
Adam Wieslaw Mazur
Frank Hallock Ebetino
Roy Lee Martin
Original Assignee
Warner Chilcott Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co Llc filed Critical Warner Chilcott Co Llc
Publication of MX2012004769A publication Critical patent/MX2012004769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen compuestos de acetal cíclico de bisfosfonato novedosos, así como también métodos de preparar los compuestos, composiciones farmacéuticas que incluyen los compuestos y la administración de los compuestos en métodos para tratar trastornos de metabolismo óseo tal como el metabolismo anormal de calcio y fosfato.
MX2012004769A 2009-10-26 2010-10-26 Compuestos de bisfosfonato para tratar transtornos del metabolismo oseo. MX2012004769A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25488609P 2009-10-26 2009-10-26
PCT/US2010/054124 WO2011056589A1 (en) 2009-10-26 2010-10-26 Bisphosphonate compounds for treating bone metabolism disorders

Publications (1)

Publication Number Publication Date
MX2012004769A true MX2012004769A (es) 2012-08-08

Family

ID=43478185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004769A MX2012004769A (es) 2009-10-26 2010-10-26 Compuestos de bisfosfonato para tratar transtornos del metabolismo oseo.

Country Status (10)

Country Link
US (3) US8314081B2 (es)
EP (1) EP2493905B1 (es)
JP (1) JP5850842B2 (es)
CN (1) CN102630227B (es)
CA (1) CA2778015C (es)
IL (1) IL219235A (es)
IN (1) IN2012DN03448A (es)
MX (1) MX2012004769A (es)
SG (1) SG10201406846XA (es)
WO (1) WO2011056589A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056589A1 (en) 2009-10-26 2011-05-12 Warner Chilcott Company, Llc Bisphosphonate compounds for treating bone metabolism disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
KR20190120430A (ko) * 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
CA2937548C (en) * 2014-02-13 2022-10-25 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2043072B (en) 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
JPH0699457B2 (ja) * 1988-08-12 1994-12-07 山之内製薬株式会社 ヘテロ環ビスフォスフォン酸誘導体およびその医薬
US4990503A (en) 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
US5039699A (en) * 1989-03-27 1991-08-13 Lederle (Japan), Ltd. Anti-peptic ulcer agent
US5227506A (en) 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI89366C (fi) * 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
JPH06508365A (ja) * 1991-06-19 1994-09-22 ジ・アップジョン・カンパニー 抗炎症剤としてのりん酸ジアルキル（ジアルコキシホスフィニル）メチル類
JPH05239075A (ja) * 1991-08-27 1993-09-17 Eisai Co Ltd 含リンイソプレノイド誘導体
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
JPH06172372A (ja) * 1991-11-06 1994-06-21 Takeda Chem Ind Ltd スクアレン合成酵素阻害剤およびその用途
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
AU6156494A (en) 1993-03-08 1994-09-26 Eisai Co. Ltd. Phosphonic acid derivatives
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
EP0705834A1 (de) 1994-07-27 1996-04-10 Ciba-Geigy Ag Azaaliphatisch Überbrückte Chinoxalin-2,3-dione
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7358361B2 (en) 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US7781418B2 (en) 2006-12-14 2010-08-24 Isis Innovation Ltd. Composition for treating bone disorders
US8618079B2 (en) 2008-09-22 2013-12-31 Isis Innovation Limited Imidazo[1,2-a] pyridinyl bisphosphonates
KR20110079669A (ko) 2008-09-22 2011-07-07 아이시스 이노베이션 리미티드 5-아자인돌 비스포스포네이트
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
WO2011056589A1 (en) 2009-10-26 2011-05-12 Warner Chilcott Company, Llc Bisphosphonate compounds for treating bone metabolism disorders

Also Published As

Publication number Publication date
US20140194389A1 (en) 2014-07-10
CN102630227A (zh) 2012-08-08
EP2493905A1 (en) 2012-09-05
SG10201406846XA (en) 2014-12-30
IL219235A (en) 2017-01-31
US20130035482A1 (en) 2013-02-07
US20110098251A1 (en) 2011-04-28
JP2013508459A (ja) 2013-03-07
IL219235A0 (en) 2012-06-28
EP2493905B1 (en) 2016-11-30
IN2012DN03448A (es) 2015-10-23
CA2778015A1 (en) 2011-05-12
CN102630227B (zh) 2016-03-23
WO2011056589A1 (en) 2011-05-12
US8314081B2 (en) 2012-11-20
CA2778015C (en) 2016-08-02
US8822435B2 (en) 2014-09-02
JP5850842B2 (ja) 2016-02-03
US8710215B2 (en) 2014-04-29

Similar Documents

Publication Publication Date Title
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2014DN09805A (es)
IN2012DN02735A (es)
IN2012DN00754A (es)
IN2014DN09804A (es)
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2011007930A (es) Conjugados de insulina cristalina.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2012004769A (es) Compuestos de bisfosfonato para tratar transtornos del metabolismo oseo.
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
WO2011023367A3 (en) Bisphosphonate-prodrugs
BR112012026098A2 (pt) métodos e composições para melhorar a osseointegração de implante.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2009011577A (es) Composiciones y metodos para distribucion de domperidona a traves de la mucosa.
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX360235B (es) Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo.

Legal Events

Date Code Title Description
FG Grant or registration